Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 186.42 ($2.35) and traded as low as GBX 165 ($2.08). Faron Pharmaceuticals Oy shares last traded at GBX 165 ($2.08), with a volume of 2,665 shares trading hands.
Faron Pharmaceuticals Oy Stock Up 0.6 %
The stock has a market capitalization of £226.21 million, a price-to-earnings ratio of -4.51 and a beta of 0.36. The firm's fifty day moving average is GBX 181.96 and its 200-day moving average is GBX 186.63. The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
